Horizon Therapeutics initiates MIRROR randomized controlled trial evaluating KRYSTEXXA
Horizon Therapeutics announced initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies. June 20, 2019